Drug Trial Radar · NCT00689936
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,623
Actual
Start
Aug 21, 2008
Primary completion
Jul 14, 2016
Study completion Jul 14, 2016
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jun 4, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
Conditions
- Multiple Myeloma
Interventions
Lenalidomide and low-dose dexamethasoneDrug
Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD. Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression
Lenalidomide plus low-dose dexamethasone given for 18 four-week cyclesDrug
lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles. Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles
Melphalan, Prednisone and ThalidomideDrug
Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)Time frame: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.
- Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final AnalysisTime frame: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months
Locations
288 sites in 19 countries. Site status is shown where the registry gives one.
University of AL Birmingham
Birmingham, Alabama
Cedar Sinai Medical Center Dept of Medicine
Los Angeles, California
University of California, San Francisco- California
San Francisco, California
Stanford University Stanford
Stanford, California
Gainesville Heme Oncology Associates
Gainesville, Florida
Baptist Cancer Institute
Jacksonville, Florida
Integrated Community Oncology Network
Orange Park, Florida
Gulf Coast Oncology
St. Petersburg, Florida
Palm Beach Cancer Institute, LLC
West Palm Beach, Florida
Southern Illinois Hematology Oncology
Centralia, Illinois
Orchard Healthcare Research, Inc.
Chicago, Illinois
John H Stroger Hospital of Cook County
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Ingalls Cancer Institute
Harvey, Illinois
Cancer Center of Kansas
Wichita, Kansas
Maine Center for Cancer Medicine Blood Disorders
Scarborough, Maine
Center for Cancer and Blood Disorders
Bethesda, Maryland
Mayo Clinic Cancer Center
Rochester, Minnesota
Billings Clinic
Billings, Montana
Arena Oncology Associates, PC
Lake Success, New York
Dakota Cancer Institute
Fargo, North Dakota
Gabrail Cancer Center Research
Canton, Ohio
University Hospitals of Cleveland
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Kaiser Permanente Northwest Oncology Hematology
Portland, Oregon
St. Luke's Hospital and Health Network
Allentown, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
The Cancer Center
Collierville, Tennessee
University of Tennessee Cancer Institute
Memphis, Tennessee
University of Texas Medical Branch
Galveston, Texas
Swedish Cancer Institute
Seattle, Washington
Fred Hutchinson Cancer Center
Seattle, Washington
Flinders Medical Centre
Bedford Park, Australia
Geelong Hospital
Geelong, Australia
Gosford Hospital
Gosford, Australia
Royal Brisbane and Women's Hospital
Herston, Australia
Cabrini Hospital
Malvern, Australia
The Royal Melbourne Hospital
Parkville, Australia
Royal Perth Hospital
Perth, Australia
Gold Coast Hospital
Southport, Australia
Showing 40 of 288 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.